Abstract: The present invention relates to a composition for improving gastrointestinal health comprising bromelain enzyme, short-chain fatty acids, specified amino acids, and vitamin D.

Abstract: The present invention provides compositions and methods for modulating the expression of Hyaluronan (HA). In particular, this invention relates to compounds, which hybridize with nucleic acid molecules encoding hyaluronan synthase (HAS), particularly HAS isoforms HAS1, HAS2 and HAS3. These compounds may range in size from oligonucleotides to full length sequences. Such compounds are exemplified to modulate proliferation, such as cancer and inflammatory disorders, such as arthritis. It will be understood, however, that the compounds can be used for any other condition in which HA is involved.

Abstract: The present invention relates to the enhancement of bioavailability of chemotherapeutic agents for the treatmnet of disease. In particular the present invention relates to a method of enhancing the bioavailability of a chemotherapeutice agent comprsing the step of administering to a submect in need thereof a therapeutically effective amount of hyaluronan.

Abstract: This application provides methods and compositions for the treatment of cancer. The application provides compositions comprising hyaluronic acid and a chemotherapeutic agent such as irinotecan that are useful in the treatment of cancer.

Abstract: This application provides methods and compositions for the treatment of cancer. The application provides compositions comprising hyaluronic acid and a chemotherapeutic agent such as irinotecan that are useful in the treatment of cancer.

Abstract: The present invention relates to the field of chemotherapy of diseases such as cell proliferation disorders including cancer. In particular, the present invention relates to the use of hyaluronan (HA) as a protective agent in the treatment of subjects. HA is administered in conjunction with a chemotherapeutic agent to facilitate the prolonged administration of a dose of the chemotherapeutic agent to be administered to a subject. Owing to the protective effects of the HA, the dose of chemotherapeutic agent may be substantially higher than a generally accepted effective dose, which would otherwise be expected to cause unacceptable side effects in the subject.

Abstract: The present invention relates to the enhancement of bioavailability of chemotherapeutic agents for the treatment of disease. In particular the present invention relates to a method of enhancing the bioavailability of a chemotherapeutic agent comprising the step of administering to a subject in need thereof a therapeutically effective amount of hyaluronan.